Onderneming PHAXIAM Therapeutics S.A. Euronext Paris
Aandelen
PHXM
FR0011471135
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,95 EUR | 0,00% | +1,20% | -35,87% |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-23 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-23 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-23 |
Cindy Fevre
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-23 |
Céline Breda
CTO | Chief Tech/Sci/R&D Officer | 54 | 23-06-23 |
Karine Charton
PRN | Corporate Officer/Principal | - | 23-06-23 |
General Counsel | - | 23-06-23 | |
Human Resources Officer | - | 23-06-23 | |
Jérôme Bailly
PRN | Corporate Officer/Principal | 45 | 23-06-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 23-06-23 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-23 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-23 |
Martine George
BRD | Director/Board Member | 76 | 23-06-23 |
Director/Board Member | 66 | 23-06-23 | |
Didier Hoch
CHM | Chairman | 68 | 23-06-23 |
Leila Nicolas
BRD | Director/Board Member | - | 23-06-23 |
Robert Sebbag
BRD | Director/Board Member | 73 | 23-06-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 6 075 105 | 5 597 574 ( 92,14 %) | 250 ( 0,004115 %) | 92,14 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
250 | 0.00% | 805 $ |
Bedrijfsgegevens
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |
- Beurs
- Aandelen
- Koers PHXM
- Koers PHXM
- Onderneming PHAXIAM Therapeutics S.A.